Sergliflozin etabonate

Sergliflozin etabonate (INN/USAN,[1][2] codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline. It did not undergo further development after phase II.

Sergliflozin etabonate
Clinical data
Routes of
administration
Oral
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H28O9
Molar mass448.468 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

Method of action

Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3][4]

Chemistry

Etabonate refers to the ethyl carbonate group. The remaining structure, which is the active substance, is called sergliflozin.

Sergliflozin
gollark: YOU PROBABLY SHOULD HAVE ANYWAY YOU POTATO.
gollark: Yes, well.
gollark: Just make the tokens tuples of `(type ("string", "int", "char"), value)`.
gollark: .... aargh I can't work on this.
gollark: I mean doing toks.append('"'+tok+'"').

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.